Table 6.

Comparison of some pathological features with MMR status in different studies

Author	High grade (%)		MI*≥ 50%		LVSI* (%)		LUS* (%)		Early stage (%)		Adjuvant therapy
	iMMR	dMMR	iMMR	dMMR	iMMR	dMMR	iMMR	dMMR	iMMR	dMMR	iMMR	dMMR
Arab et al.,2021	23.37	21.05	39.42 mm	54.13 mm	22.1	34.8	26	52.2	83.1	91.30	57.1	73.9
	P: .543		P: .021		P: .217		P .018		P .018		P: .148
Gordha et al., 2020	20	29							88	80
	p<0.01								p<0.01
Backes et al, 2019	9	28.1	70.7	57.8	33.1	45.3	9.4	27.8			45.9	43.8
	p<0001		p: .073		p: .096		p<0001				p .879
Kim KS et al. 2018	58.2	50			53.4	65.4			79	71.6
	P: .003				p: .007				p: .13
Nagle et al, 2018	21.9	25			23	33.74			88.3	86.9	34	45.4
	p: .028				p: .02				p: .44		p: .03
Kim J et al, 2018	42.5	64.5	28.6	40	12.1	31.8			91.4	75.6	23.4	44.4
	p: .011		p: 0.15		p: .003				p: .014		p: .007
Cosgrove et al, 2017	17.1	21.55	26.9	34.5	18.5	40.5			83.7	71.5	29	40.9
	p: .002		p: .024`		p: <.001				p: .015		p: .045
McMeekin et al, 2016	13.14	18.45	25.68	28.98	17.25	32.23			86.7	80.44
	p: .01		NS		p: .001				p: .001

MI: Myometrial invasion; LVSI: Lympho-vascular space invasion; LUS: lower uterine segment